Diabetes is a group of metabolic diseases that have taken the center stage across the world as one of the most profound and lasting conditions that significantly reduces the quality of life for people. It has grown to epidemic proportions and approximately 400 million people currently live with diabetes across the world and this number is expected to expand to approximately 550 million by 2030. It is a peptide hormone responsible for regulating blood glucose levels. Though there is no well-defined etiology for the occurrence of type 1 diabetes, it is mostly associated with a genetic disorder or an unexpected immune system's reaction that erroneously destroys the insulin-producing cells of the islet. Major symptoms include feeling thirsty, frequent urination, constant fatigue, weight loss, and muscle loss, slow wound healing, blurred vision and repeated episodes of thrush.
The only treatment widely recommended by medical practitioners is insulin intake for a lifetime. HbA1c test is considered a critical test to infer the presence of glucose in the blood for the past couple of months and also plays an important role in laying down the treatment regime specific to individual patients. The insulin treatment algorithm can be defined on the basis of insulin preferred by the physicians that would give maximum efficacious outputs to the patient. The broad classification of types of insulins is based on their onset of action and duration of action – rapid-acting, short-acting, long-acting, intermediate-acting and pre-mixed insulin. Giant pharmaceutical companies like Novo Nordisk, Eli Lilly, and Sanofi are the key players in this market with Novo Nordisk being the market leader.
The insulin market is also categorized on the basis of its origin and technological advancement achieved in delivering the drug to the human body. Prefilled insulin delivering devices currently govern approximately two-third of the total insulin volume injected to human beings globally. Insulin derived from human origin takes up the maximum market share compared to insulin derived from animal sources. The new category of insulins called modern insulins widely known as insulin analogs that are produced through recombinant DNA technology is expected to lead the future market enabling patients to have better glycaemic control.
Lantus from Sanofi is a leading product in the long-acting insulin segment competing with Levemir from Novo Nordisk. Other key products in this market are – Humalog, Novolog, Apidra, Velosulin, NPH, Lente, Humulin, Novolin, etc. New devices such as insulin pumps are making lives easier since patients do not have to constantly bother with injections. These devices and a new class of devices called artificial pancreas are expected to reduce patient discomfort and improve the quality of life for diabetics significantly.
Though North America is the largest insulin market followed by Europe, tremendous growth has been identified in Asia precisely in India and China due to the large diabetic population diagnosed in this region. Other emerging geographic regions for the insulin drugs market with reasonable growth rates are Latin America, the Middle East, and Africa.
The below mentioned quantitative and qualitative analysis is subject to enhancement and refinement during the course of research.
Quantitative Analysis
The report analyses and estimates the market by:
• Product Segment/Sub-segment Types
• Technology
• Application
• Market Share Analysis – segments, players, geographies
• Geographic Analysis
Comments
Post a Comment